



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/564,615	Dmitry Dmitrievich Genkin	06-1665

INTERNATIONAL APPLICATION NO.	
PCT/RU03/00304	
I.A. FILING DATE	PRIORITY DATE
01/27/2005	

33055  
 PATENT, COPYRIGHT & TRADEMARK LAW GROUP  
 430 WHITE POND DRIVE  
 SUITE 200  
 AKRON, OH 44320

CONFIRMATION NO. 9480

371 FORMALITIES LETTER



\*OC000000022366703\*

Date Mailed: 03/01/2007

## NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

**For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:**

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ [ebc@uspto.gov](mailto:ebc@uspto.gov)

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.  
<https://sportal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or

visit our website at <http://www.uspto.gov/ebc>.

**If you are not using EFS-Web to submit your reply, you must include a copy of this notice.**

VIRGINIA L IRBY

Telephone: (703) 308-9140 EXT 229

**PART 1 - ATTORNEY/APPLICANT COPY**

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/564,615	PCT/RU03/00304	06-1665

FORM PCT/DO/EO/922 (371 Formalities Notice)



3FW ✓  
Box 299  
Utility Patent  
Ser. No. 10/564,615

**BEFORE THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Dmitry Dmitrievich Genkin ) Date: April 30, 2007  
Serial No: 10/564,615 ) Group Art Unit: N/A  
Filed: 01/27/2005 ) Examiner: N/A  
For: **Method for treating oncological, virulent** )  
**and somatic diseases, method for** )  
**controlling treatment efficiency,** )  
**pharmaceutical agents and composition** )  
**for carrying out said treatment** )

**Certificate of Mailing**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450 on 04/30/07 (date). Typed or printed name of person signing this certificate.

JOHN D. GUGLIOTTA  
Signature [Signature]

Hon. Commissioner of Patents and Trademarks  
Alexandria, VA 22313-1450

**Certificate of Transmission**

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. (571) 273-8300 on \_\_\_\_\_ (date).

Printed name of person signing this certificate


Signature \_\_\_\_\_

**AMENDMENT**

Dear Examiner:

Please correct the copy of the sequence by replacing the formerly filed sequence list with the new one submitted herein. The content of the present sequence listing is identical to that information recorded in computer readable form. No new matter is introduced.

Respectfully submitted,



---

John B. Gugliotta, P.E., Esq.  
Registration No. 36,538  
430 White Pond Drive, Suite 200  
Akron, OH 44320  
Ph: (330) 253-5678  
Facsimile (330) 253-6658